Rare disease (orphan) designations

  • Email
  • Help

This page allows you to find information on rare disease (orphan) designations based on applications that have been assessed by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP).

An orphan designation allows a pharmaceutical company to benefit from incentives from the European Union to develop a medicine for a rare disease, such as reduced fees and protection from competition once the medicine is placed on the market. Applications for orphan designation are examined by the COMP, which adopts an opinion that is forwarded to the European Commission. The European Commission then decides whether to grant an orphan designation for the medicine in question.

For more information, see Orphan designation.

Document status

Include:

Browse by letter

Search for active substance by letter and/or number:

Search by keyword

Search for keyword:

Download results to spreadsheet
EPAR Search results
Active substance Disease / condition Date of decision Decision Medicine name

Everolimus

Treatment of renal cell carcinoma 2007-06-05 Withdrawn Afinitor

Fenretinide

Treatment of primary malignant bone tumours 2007-01-25 Withdrawn  

Fenretinide

Treatment of soft tissue sarcoma 2007-01-29 Withdrawn  

Fingolimod

Treatment of chronic inflammatory demyelinating polyneuropathy 2010-02-02 Withdrawn  

Fluorouracil

Treatment of glioblastoma 2000-10-18 Withdrawn  

Folic acid to be used with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine

Diagnosis of positive folate-receptor status in ovarian cancer 2012-09-10 Withdrawn Neocepri

Fomepizole

Treatment of methanol poisoning 2001-05-30 Withdrawn  

Fumagillin

Treatment of diarrhoea associated with intestinal microsporidial infection 2002-02-04 Withdrawn  

GM-CSF receptor antagonist

Treatment of juvenile myelomonocytic leukaemia 2002-03-18 Withdrawn  

Givinostat

Treatment of systemic-onset juvenile idiopathic arthritis 2010-01-28 Withdrawn  

Glutathione-pegylated liposomal doxorubicin hydrochloride

Treatment of glioma 2010-09-20 Withdrawn  

Glutathione

Treatment of cystic fibrosis 2006-04-11 Withdrawn  

H-Tyrosine-Glycine-Phenylalanine-Glycine-Glycine-OH (Chemical)

Treatment of chronic idiopathic myelofibrosis 2003-10-20 Withdrawn  

H-Val-Ile-Val-Lys-Leu-Ile-Pro-Ser-Thr-Ser-Ser-Ala-Val-Asp-Thr-Pro-Tyr-Leu-Asp-Ile-Thr-Tyr-His-Phe-Val-Ala-Gln-Arg-Leu-Pro-Leu-OH

Treatment of Myasthenia Gravis 2006-08-28 Withdrawn  

HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS)

Treatment of renal cell carcinoma 2007-02-14 Withdrawn  

Heparin sodium (inhalation use)

Treatment of cystic fibrosis 2005-12-22 Withdrawn  

Heparin-Sodium

Treatment of idiopathic pulmonary fibrosis 2004-09-02 Withdrawn  

Homoharringtonine

Treatment of acute myeloid leukaemia 2004-10-20 Withdrawn  

Homoharringtonine

Treatment of chronic myeloid leukaemia 2004-09-02 Withdrawn  

Human C1 inhibitor

Treatment of angioedema caused by C1 inhibitor deficiency 2009-10-08 Withdrawn  

Human Milk Fat Globule 1 / Yttrium (90Y) human Milk Fat Globule 1 - S p isothiocyanatobenzyl-diethylenetriaminepentaacetic acid

Treatment of ovarian cancer 2001-05-30 Withdrawn  

Human Staphylococcus aureus polyclonal immunoglobulin and human Staphylococcus epidermidis polyclonal immunoglobulin

Late onset sepsis in premature infants of less or equal than 32 weeks of gestational age 2005-12-13 Withdrawn  

Human anthrax immunoglobulin

Treatment of inhalation anthrax disease 2009-11-17 Withdrawn  

Human anthrax monoclonal antibody

Treatment of inhalation anthrax disease 2011-04-15 Withdrawn  

Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh

Treatment of epidermolysis bullosa 2011-06-21 Withdrawn